BUY Jubilant Ingrevia Limited — Kshitija Salvi, Globe Capital Market
byKshitija Salvi, Globe Capital MarketHorizon: NA (inferred Swing (≤2wk))3 Aug 2026via CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Jubilant Ingrevia Ltd announced the outcome of its Board Meeting held on July 22, 2026. The board approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 20
BSE · Board Meeting·22 Jul · 3w ago
Jubilant Ingrevia Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
NSE · Outcome of Board Meeting·22 Jul · 3w ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.
Other calls on Jubilant Ingrevia
- BUY — Siddharth Rai Mangala28 Sept 2026 · ~2 weeks · target ₹720 · SL hit
- BUY — Shrikant Chouhan, Kotak Securities25 Sept 2026 · ~1 year · target ₹775 · SL hit
- BUY — Axis Securities24 Sept 2026 · ~1 year · target ₹705 · Active
- BUY — Kotak Securities23 Sept 2026 · ~1 year · target ₹1,010 · Active
- BUY — Shrikant Chouhan, Kotak Securities1 Sept 2026 · Next day · target ₹710 · Expired
More from Kshitija Salvi, Globe Capital Market
- BUY Laurus Labs11 Sept 2026 · ~2 weeks · target ₹2,140 · SL hit
- BUY Ather Energy10 Sept 2026 · ~2 weeks · target ₹1,760 · SL hit
- BUY Cholamandalam Investment and Finance Company10 Sept 2026 · ~2 weeks · target ₹1,985 · SL hit
- BUY Adani Ports and Special Economic Zone9 Sept 2026 · ~2 weeks · target ₹1,900 · Expired
- BUY Ajanta Pharma8 Sept 2026 · ~2 weeks · target ₹3,825 · SL hit

